Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Overall Survival (OS): Cluster of Differentiation (CD)-targeted immunotherapy significantly improved overall survival in acute lymphoblastic leukemia (ALL) patients compared to conventional chemotherapy, with a pooled odds ratio (OR) of 2.11 (95% confidence interval (CI), 1.76-2.53), demonstrating a robust survival benefit.
• Relapse-Free Survival (RFS): Patients treated with CD-targeted immunotherapy had significantly higher relapse-free survival rates than those on conventional chemotherapy, with a pooled OR of 2.25 (95% CI, 1.62-3.14).
• Complete Remission (CR) and Minimal Residual Disease (MRD) Negativity: CD-targeted immunotherapy led to higher rates of complete remission (OR 1.70, 95% CI 1.07-2.69) and minimal residual disease negativity (OR 2.98, 95% CI 1.17-7.58) compared to conventional chemotherapy.
• Patients receiving CD-targeted immunotherapy for acute lymphoblastic leukemia had a significantly lower risk of febrile neutropenia compared to those receiving conventional chemotherapy, with a pooled OR of 0.22 (95% CI, 0.08-0.58).
• There is no population type or subgroup information available in the reviewed studies.